Abstract: The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.
Type:
Grant
Filed:
January 19, 1995
Date of Patent:
January 4, 2000
Assignee:
N.V. Innogenetics S.A.
Inventors:
Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde
Abstract: An isolated and purified nucleic acid comprising:a nucleotide sequence which has at least 50% sequence identity, with any of the nucleotide sequences coding for polypeptides containing in their pepridic chains:the amino acid sequence of 311 amino acids of FIGS. 2 or 3,or a fragment of this sequence being such that it is able to produce antibodies capable of forming a complex with the amino acid sequence of FIG. 2 or 3,or an amino acid sequence having a percentage of homology of at least 50%, with the amino acid sequence of FIG. 2 or 3,or a sequence able to form a complex with antibodies raised against the amino acid sequence of FIG.
Type:
Grant
Filed:
October 13, 1994
Date of Patent:
November 9, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Lucia Fransen, Kathleen Devos, Andre Van De Voorde, Hugo Van Heuverswyn
Abstract: The invention relates to nucleic acids which contain particularly a nucleotide sequence extending from the extremity constituted by the nucleotide at position (1) to the extremity constituted by the nucleotide at position (1211) represented on the figure, to the polypeptides coded by said nucleic acids. The polypeptides of the invention can be used for the diagnosis of tuberculosis, and can also be part of the active principle in the preparation of a vaccine against tuberculosis.
Type:
Grant
Filed:
October 4, 1993
Date of Patent:
September 21, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Jean Content, Lucas De Wit, Jacqueline De Bruyn
Abstract: The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to about the maximum number of nucleotides of the spacer region and more preferably from about 15 to about 100 nucleotides to be used for the detection of non-viral microorganisms.
Abstract: The invention relates to recombinant polypeptides and peptides which can also be used for the diagnosis of tuberculosis. The invention also relates to a process for preparing the above polypeptides and peptides, which are in a state of biological purity such that they can be used as part of the active principle in the preparation of vaccines against tuberculosis. The invention additionally relates to nucleic acids coding for said polypeptides and peptides.
Type:
Grant
Filed:
May 22, 1995
Date of Patent:
June 29, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
Abstract: This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the gp41 region of the human immunodeficiency virus type 1 (HIV-1), strain Ant70. This peptide has the following amino acid sequence: NH.sub.2 -Leu-Trp-Gly-Cys-Lys-Gly-Lys-Leu-Val-Cys-CO.sub.2 H. The invention also relates to the use of this peptide, particularly when biotinylated in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides, for the in vitro determination of HIV-1-specific antibodies.
Abstract: The invention relates to tumor necrosis factor muteins characterized in that the TNF-.alpha. amino acid sequence is mutated, or deleted totally or partially, in the region containing position 101 to 116 in such a way that:either the lectin-like activity is reduced with respect to TNF-.alpha.,or the toxic activity is reduced with respect to TNF-.alpha.; and providing that said muteins have largely retained the tumoricidal activity of TNF-.alpha.; and with said muteins possibly containing in their peptidic chain additional modifications consisting of substitutions and/or deletions and/or additions of one or several amino acid residues, and with said muteins being characterized in that they have retained the aforementioned activities; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 15, 1995
Date of Patent:
April 6, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Rudolph Lucas, Patrick De Baetselier, Lucia Fransen, Erwin Sablon
Abstract: The invention relates to a method for typing or subtyping one or more HLA-B alleles characterized by the sequence GCCA at position 30 to 33 of exon 2 (with said numbering being according to Zemmour and Parham, 1992), liable to be present in a sample, with said method comprising at least the following steps: (i) amplifying HLA-B alleles with at least one 5' end amplification primer selected from the following list: 5' -AGGTATTTCTACCCGCCA-3' (B25P) or sequence variants thereof, in combination with an appropriate 3' end primer being chosen from the same alleles as the above defined 5' end primers, with said 5' and 3' end primers being possibly labelled; and, (ii) hybridizing the amplified product, being labelled during or after amplification, at appropriate conditions with one or more suitable probes selected from region 15 to 261 of the HLA-B exon 2 region, with said numbering being according to Zemmour and Parham 1992, (iii) washing at appropriate washing conditions, (iv) detecting the hybrids formed; and, (v)
Type:
Grant
Filed:
October 23, 1995
Date of Patent:
March 16, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Marc Andrien, Etienne Dupont, Rudi Rossau, Ilse De Canck
Abstract: The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
Type:
Grant
Filed:
February 15, 1995
Date of Patent:
January 19, 1999
Assignee:
N.V. Innogenetics S.A.
Inventors:
Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde
Abstract: The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
Type:
Grant
Filed:
January 19, 1995
Date of Patent:
December 1, 1998
Assignee:
N.V. Innogenetics S.A.
Inventors:
Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde
Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
Type:
Grant
Filed:
November 14, 1994
Date of Patent:
April 7, 1998
Assignees:
Merck & Co.,. Inc., N. V. Innogenetics S.A.
Inventors:
Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer
Abstract: The subject invention relates to amino acid sequences derived from peptide (Glu.sup.1,8, Leu.sup.11,17) 18A, comprising:Glu-Trp-Leu-A-Ala-B-Tyr-C-Lys-Val-D-Glu-Lys-Leu-Lys-Glu-Leu-Phe,wherein A is Lys, Glu or Asp; B is Phe, Glu or Asp; C is Glu, Lys or Arg;and D is Leu, Glu or Asp. The amino acid sequences form complexes with phospholipids, and are useful for the treatment of cardiovascular disease.
Type:
Grant
Filed:
December 23, 1994
Date of Patent:
March 31, 1998
Assignee:
N.V. Innogenetics, S.A.
Inventors:
Maryvonne Rosseneu, Robert Brasseur, Robert Deleys, Christine Labeur
Abstract: Methods of detection of the Gram-negative bacterium, Branhamella catarrhalis are disclosed. These methods use nucleic acid hybridization probes derived from the bacterium's ribosomal RNA genes.
Abstract: The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to about the maximum number of nucleotides of the spacer region and more preferably from about 15 to about 100 nucleotides to be used for the detection of non-viral microorganisms.
Abstract: The invention relates to a polypeptide containing a sequence of contiguous amino acids of the polypeptide sequence coded by exon 17 of the cDNA of the APP 770 gene, with said sequence of contiguous amino acids being such that:it has from 5 to the total number of amino acids coded by said exon 17,and it contains the amino acid corresponding to codon 692 in the cDNA of the APP 770 gene and which is alanine substituted for glycine. (no figure).
Type:
Grant
Filed:
October 8, 1993
Date of Patent:
June 11, 1996
Assignee:
N. V. Innogenetics S.A.
Inventors:
Christine Van Broeckhoven, Jean-Jacques Martin, Lydia Hendriks, Patrick Cras